Suven Life Sciences announces initiation of phase 3 trial of Alzheimer's drug

SUVN-502 (Masupirdine), a lead clinical candidate, has undergone a phase 2 study on 564 patients for moderate Alzheimer's disease without meeting the primary end point.

However, after an in-depth analysis of the data and intense dialogue with key opinion leaders, Suven Life Sciences has planned a new clinical trial for the treatment of agitation and aggression in Alzheimer's type dementia.

Prior to the initiation of the Phase 2A study, SUVN-502 had successfully undergone two phase 1 studies in Switzerland and the USA on 122 healthy young and elderly male populations with no major adverse events and no serious adverse events.

Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, this Phase 3 SUVN-502 for Agitation and aggression in Alzheimer's type dementias, ongoing Phase 2 SUVN-G3031 for sleep disorders (Narcolepsy), Phase 1 completed SUVN-911 for Major Depression and Disorder (MDD) and Phase 1 completed SUVN-D4010, a Dual Mechanism of Action (Disease Modifying and Symptomatic Treatment Potential for AD) Gastro-Intestinal Motility Disorders. Apart from this Suven has 11 molecules in development pipeline.